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Introduction
Approximately one in eight adults has chronic kidney
disease (CKD) in Japan, and the prevalence rate is
expected to rise steeply due to the aging of the population
in this country. In patients with CKD, quite a few medi-
cations require the dosage reduction or discontinuation
because of their reduced urinary excretion and the
increased risk of further renal impairment. Therefore, CKD
patients are often treated by insufficient amounts of the
medications, even though they may suffer from various
complications. Moreover, it is empirically known that
drug-induced kidney injury (DKI) accelerates the pro-
gression of renal failure, while it is not superficially ranked
as a primary cause of kidney disease.
In this context, the early detection, prevention, and
treatment of DKI are very important issue in preventing the
progression of CKD and the development of renal failure.
However, there are no comprehensive and practical
guideline on the diagnosis and treatment of DKI for CKD
patients and on dosage adjustments for these patients.
In response to this need, a clinical practice guideline for
DKI was developed with the support of a Health and
Labour Science Research Grant from the Ministry of
Health, Labour, and Welfare (MHLW) and the Japan
Agency for Medical Research and Development (AMED)
for Practical Research Project for Renal Diseases, ‘‘Early
detection and treatment of drug-induced kidney injury that
aggravate chronic kidney disease.’’ This guideline was
established by doing a clinical survey on DKIs, evaluating
clinicopathological factors, investigating the methods of
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the early detection of the disease, and analyzing animal
models. The present article represents a Committee of
Clinical Practice Guideline for DKI. We collected sup-
portive evidence and analyzed data, focusing on several
clinical questions that have practical importance.
Evidence levels, total evidence grades
and recommendation levels
The level of each evidence was determined according to
the method of previous Japanese Clinical Practice Guide-
lines, namely, as using the abridged English version of
evidence-based clinical practice guidelines for CKD [1]. In
brief, evidence was classified into six levels based on the
study design, and was arranged roughly from the most
reliable study type (Level 1) to the least reliable (Level 6).
These levels do not necessarily represent rigorous scientific
standards. As a result, total evidence grades for each
clinical question were determined based on the evidence
level for each question. Finally, the members of the com-
mittee discussed the matter and decided on the recom-
mendation levels based on the total evidence grades or
expert consensus.
Evidence levels
Level 1: systematic review/meta-analysis.
Level 2: at least one randomized controlled trial (RCT).
Level 3: a non-randomized controlled trial.
Level 4: an analytical epidemiologic study (cohort study or
case–control study) or a single-arm intervention study (no
controls).
Level 5: a descriptive study (case report or case series).
Level 6: opinion of an expert committee or an individual
expert, which is not based on patient data.
Total evidence grades
Grade A (strong): the scientific basis is strong.
Grade B (moderate): the scientific basis is moderate.
Grade C (weak): the scientific basis is limited.
Grade D (very weak): there is no scientific basis.
Recommendation levels
Level 1: strongly recommended.
Level 2: weakly recommended or suggested.
Level undefined: without recommendation.
Section 1. Definition, classification, and practice
of DKI
The definition of DKI is a new onset of kidney injury or the
worsening of an existing kidney injury due to drug
administration. DKI can be classified based on the mech-
anism of pathogenesis, as well as on the damaged segment
of the kidney. The classification based on the mechanism
of pathogenesis is as follows: (1) toxic kidney injury (direct
toxicity); (2) acute interstitial nephritis (AIN) due to
allergic mechanism (hypersensitivity and direct toxicity);
(3) indirect toxicity, such as electrolyte abnormalities and
decrease of renal blood flow; and (4) obstruction of urinary
tract. The classification based on the damaged segment of
kidney is as follows: (1) glomerular injury; (2) tubular
injury; (3) interstitial injury; and (4) vascular injury. The
criteria for diagnosis are as follows: (1) new onset of
kidney injury after the start of the administration of the
candidate agent and (2) improvement or stoppage of the
progression of the kidney injury after the cessation of the
candidate agent, and all other causes can be ruled out. The
cornerstone of treatment is the identification and cessation
of the candidate agent as soon as possible.
Question 1. Is eosinouria a useful biomarker
for the early diagnosis of DKI?
Statements
1. Eosinouria can be detected in DKI due to AIN, but it is
not a useful biomarker for the diagnosis of DKI
because of its high rate of false negatives (recom-
mendation: Level 2; total evidence: Grade C).
2. If eosinouria is detected in acute kidney injury (AKI),
acute tubular necrosis (ATN) can be excluded as a
cause of the AKI (recommendation: Level 2; total
evidence: Grade C).
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Question 2. Is a renal biopsy useful
for the diagnosis of DKI?
Statements
1. Renal biopsy is a useful tool for predicting the renal out-
come of DKI and determining further treatment strategies
(recommendation: Level 2; total evidence: Grade C).
2. Renal biopsy is a useful tool for the differential
diagnosis between drug-induced renal tubular or
interstitial injuries and other causes (recommendation:
Level 2; total evidence: Grade C).
3. By renal biopsy, the glomerular histology can be
confirmed and a valuable information on whether or
not to suspect DKI can be available (recommendation:
Level undefined; total evidence: Grade C).
Section 2. Overview of the epidemiology of DKI
in Japan
To clarify the epidemiology of DKI in Japan, we reviewed
the reports of DKI for elderly persons from the study of a
Health and Labour Science Research Grant from the
Ministry of Health, Labour, and Welfare (2007–2009) and
analyzed the data of the Japan-Kidney Disease Registry (J-
KDR) from 2007 to 2012.
In the reports of DKI for elderly persons (2007–2009),
DKI accounted for approximately 1 % of all admitted
patients in the hospitals of 47 representative nephrologists.
The major drugs inducing renal injury were non-steroidal
anti-inflammatory drugs (NSAIDs) in 25.1 % of cases,
anti-cancerous drugs in 18.0 %,antibiotic agents in 17.5 %,
and radio-contrast agents in 5.7 %. Of these cases, 54.6 %
were of the direct renal injury type. Moreover, the kidney
function of 36.5 % of these patients did not recover.
A total of 231 cases of DKI, including 224 renal-biopsy-
proven cases, had been registered on J-KDR in 2007–2012
(1.42 % of 15,821 cases). The frequency of DKI increased
with aging. Elderly patients in their 70s showed a three times
higher frequency of DKI as compared to less than 10 year
(1.83 vs. 0.65 %). The major clinical diagnoses of these
cases were DKI in 118 cases (51.1 %), nephrotic syndrome
in 42 cases (18.2 %), chronic nephritic syndrome in 42 cases
(17.7 %), and rapidly progressive nephritic syndrome in 19
cases (8.2 %). The pathological findings of these cases were
glomerular injuries in 67 cases (29.0 %), acute tubule-in-
terstitial injuries in 60 cases (26.0 %), chronic tubule-inter-
stitial injuries in 55 cases (23.8 %), and sclerotic glomerular
lesion and/or nephrosclerosis in 18 cases (7.8 %). Both acute
and chronic tubulo-interstitial injuriesweremainly related to
the clinical diagnosis of DKI. On the other hand, nephrotic
syndrome mainly due to membranous nephropathy was the
major cause of glomerular injuries in 44.4 %. The preva-
lence of these diagnosis was peaked in the 60s and 70s in all
categories, excepting for chronic tubulo-interstitial injuries,
which peaked in their 30s and 40s. According to the risk
category of CKD (heat map), 80.6, 75.9, and 40.9 % of acute
and chronic tubulo-interstitial injuries and glomerular injury
were categorized as high-risk (red zone) cases, respectively.
The causative drugs identified in 71 cases, which
included bucillamine in 26 cases with membranous
nephropathy, gemucitabine in 3 cases with thrombotic
microangiopathy, and propyl thiouracil in 3 cases with
ANCA-related nephritis.
Section 3. Treatment of DKI
Prompt treatment based on the mechanisms of DKI is
important to achieve recovery in renal function. DKI can
be divided into four major categories as follows: dose-
dependent direct renal drug toxicity, dose-independent
renal drug toxicity associated with immunological reac-
tions, indirect renal toxicity caused by decreased renal
blood flow and electrolyte disorders, and intratubular pre-
cipitation of drug crystals with low solubility (see ‘‘Intro-
duction’’). The primary treatment is the discontinuation of
the presumed causative drugs in all the cases. Steroid
therapy may be considered when renal dysfunction remains
even after the withdrawal of the presumed causative drug.
Question 3. Is treatment with steroids better
than that without steroids to improve renal
function in patients with drug-induced AIN?
Statements
1. Steroid therapy may be considered when renal dys-
function remains even after the withdrawal of the
presumed causative drug (recommendation: Level 2;
total evidence: Grade C).
Section 4. Medication for patients with reduced
kidney function
A change of the drug regimen(s) (such as a reduction of the
dosage or increase of the dosing interval) should be con-
sidered when using drugs excreted by kidneys in patients
with renal impairment. Therefore, precise evaluation of
renal function by the estimation of the glomerular filtration
rate (eGFR) is important before the prescription. Several
Clin Exp Nephrol (2016) 20:827–831 829
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equations for evaluating renal function have been devel-
oped; however, careful consideration is needed, because
these equations also have limitations for their usage.
Question 4. Is intrinsic creatinine clearance (CCr)
more suitable than eGFR equation
as an appropriate evaluation of the renal function
for the adjustment of the drug dosage?
Statements
1. The utility of eGFR is variable among clinical condi-
tions. It is preferable to use intrinsic CCr in patients,
whose muscle mass is decreasing, such as those with
sarcopenia and bony body patients (recommendation:
Level 2; total evidence: Grade C).
2. Cystatin C-based GFR can be used in patients, whose
muscle mass is decreasing (recommendation: Level 2;
total evidence: Grade C).
3. The eGFR equation for the adjustment of the drug
dosage is limited in its accuracy (recommendation:
Level 2; total evidence: Grade C).
Section 5. Analgesic-related kidney injury
NSAIDs and acetaminophen are major analgesics. NSAID-
related kidney injuries usually involve ischemic damage due
to the inhibition of cyclooxygenase, and in clinical settings,
NSAID-related kidney injuries often present as acute kidney
injuries. As other types of NSAID-related kidney injuries,
AIN and interstitial nephritis complicated with nephrotic
syndrome occur rarely. By contrast, acetaminophen abuse is
known to result in chronic renal failure due to renal papillary
necrosis, calcinosis, and chronic interstitial nephritis. The
primary treatment for all analgesic-related kidney injuries is
the discontinuation of the causative medication.
Question 5. Do selective cyclooxigenase-2 (COX-2)
inhibitors cause fewer kidney injuries
than nonselective COX inhibitors?
Statements
1. NSAIDs, including selective COX-2 inhibitors, may
cause acute kidney injuries. The occurrence rate of
acute kidney injuries induced by selective COX-2
inhibitors and nonselective COX inhibitors showed no
significant difference (recommendation: Level 2; total
evidence: Grade A).
2. The occurrence rate of kidney dysfunction due to long-
term usage showed no significant difference between
selective COX-2 inhibitors and nonselective COX
inhibitors (recommendation: Level 2; total evidence:
Grade B).
Section 6. Antimicrobial-agent-related kidney
injury
The frequency of antimicrobial-agent-related kidney injury
has recently increased because of the increase in the num-
bers of elderly patients and CKD patients. In particular,
aminoglycoside antibiotics and glycopeptide-based drugs
(vancomycin) need to be used carefully in CKD patients. In
the administration of antibiotics to CKD patients, careful
consideration of dose adjustments and dosing intervals is
necessary, depending on renal function. Renal injury due to
aminoglycoside antibiotics and vancomycin is considered to
be concentration dependent and has been known to be
associated with the trough level. Therapeutic drug moni-
toring (TDM) of drug levels and microbial sensitivities is
generally the best guide to the use of antimicrobial agents in
patients with impaired drug excretion.
Question 6. Does TDM cause fewer kidney injuries
than non-monitoring in the use of vancomycin
for methicillin-resistant staphylococcus aureus
(MRSA)-infected patients?
Statements
1. Regular TDM can prevent kidney injuries due to the
use of vancomycin for MRSA-infected patients (rec-
ommendation: Level 1; total evidence: Grade A).
2. Regular TDM can significantly secure clinical efficacy
in the use of vancomycin for MRSA-infected patients
(recommendation: Level 1; total evidence: Grade A).
3. Trough-level monitoring of vancomycin is useful in
patients with unstable renal function or who require
long therapeutic periods (recommendation: Level 1;
total evidence: Grade B).
Section 7. Immunosuppressive drugs for nephritic
and/or nephrotic syndrome
With regard to immunosuppressive drugs used in the
treatment of nephritic and/or nephrotic syndrome, renal
dysfunction may have influence on the effects of these
drugs that originally have nephrotoxicity. It should be
830 Clin Exp Nephrol (2016) 20:827–831
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considered that these medications sometimes cause DKI,
especially in those with urinary tract excretion. In addition,
elderly patients often have higher risk for accelerating DKI.
Question 7. Does dose adjustment of cyclosporine
by regular TDM lead to less nephrotoxicity
in patients with nephrotic syndrome?
Statements
1. Regular TDM can prevent proximal tubular injury due
to the acute toxicity of cyclosporine (recommendation:
Level 1; total evidence: Grade A).
2. Regular TDM can prevent microangiopathy and inter-
stitial lesions (striate tubulo-interstitial fibrosis) due to
the chronic toxicity of cyclosporine (recommendation:
Level 2; total evidence: Grade B).
3. Potential nephrotoxicity due to the long-term cyclos-
porine use is histologically assessed by renal biopsy, if
necessary (recommendation: Level 2; total evidence:
Grade B).
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